The psilocybin-dementia case study produces a hype-then-correction cycle by August 11, 2026: at least two mainstream outlets (top-50 circulation/traffic) publish coverage overstating the n=1 findings, followed by at least one published expert rebuttal, fact-check, or scientist-authored corrective op-ed.

A single case study (meaning one patient, not a proper trial) about psilocybin possibly helping someone with dementia is likely to get picked up by major news outlets and reported as much bigger news than it actually is. Then experts will push back publicly and explain why one patient's story doesn't prove anything. This cycle — hype, then correction — has happened before with psychedelics research.

Pattern-matched against five prior n=1 psychedelic media cycles by the journalist agent, with independent agreement from neuroscientist and fda_reviewer (zero dissent). The 'What to know' explainer framing already in circulation is the documented first phase. Caregiver demand for dementia interventions amplifies distortion incentives. Resolution requires both legs: documented overstatement AND a published corrective — either missing resolves FALSE.